2016 Annual Meeting of Stockholders. October 20, 2016

Transcription

1 2016 Annual Meeting of Stockholders October 20, 2016

2 Safe Harbor Statement Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization, if any, of GenVec s proposed product candidates (such as marketing, regulatory, patent, product liability, supply, competition and other risks); dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec s business, financial conditions and results of operations are contained in GenVec s filings with the U.S. Securities and Exchange Commission (SEC), which are available at The forward-looking statements speak only as of the date of this presentation, and GenVec assumes no duty to update forward-looking statements. 1

3 GenVec Highlights Pioneering biotechnology company focused on leveraging its proprietary AdenoVerse gene delivery platform to develop cutting-edge therapeutics and vaccines Deep expertise in adenovector development with established and proven capabilities in translating scientific concepts to clinical products Clinical-stage product in hearing loss and balance disorders (partnered with Novartis) Genetically modified neural stem cell program for oncology (partnered with TheraBiologics) Expanding gene and cell therapy pipeline 2

4 GenVec Pipeline Discovery Preclinical Phase 1 Phase 2 Phase 3 Approved Hearing Loss [Novartis] Neural Stem Cell (NSC) Therapeutics [TheraBiologics] Respiratory Syncytial Virus, RSV Herpes Simplex Virus 2, HSV-2 Malaria [LMIV, NMRC] Foot & Mouth Disease in Cattle [DHS, USDA; Commercial license Merial, a Sanofi co.] Key: Therapeutics Vaccines [ Product Partner(s) ] 3

5 Regenerative Medicine Example CGF166 Novartis Partnership A novel therapy for hearing loss and imbalance disorders A multi-deleted Ad5 vector carrying the Atonal gene (Hath 1) Induces supporting cells in the inner ear to differentiate into sensory cells Proven ability to deliver material to the cochlea and vestibular system Demonstrated efficacy in various models (explants and in vivo) Subject of a Phase 1/2 clinical study designed to evaluate safety and efficacy 4

6 Clinical Plan Overview Trial Design Multicenter trial of 26 to 45 patients with severe to profound hearing loss Part A: Safety Single, 3-patient cohort Dose: 20 µl Part B: Dose Volume Escalation 2-5 cohorts of 3 patients each Dose volume between 30 µl and 90 µl Part C: Efficacy Single cohort of 20 patients at dose determined by Part B Option to resize 5

7 The AdenoVerse Advantage Adenovector Advantages Efficient transduction in dividing cells and non-dividing cells Non-integrating transgene limits probability of disturbing vital cellular genes AdenoVerse Strengths Vectors with no or very low seroprevalence Featuring Tunable Tropism option to allow cell-type specific gene delivery Large packaging capability (up to 12 kb) with multiple expression cassettes Improved safety with multiple deletions in vector genomes Administered to over 3,000 clinical study subjects Commercializable platform with efficient manufacturing process and attractive cost of goods Strong IP position 6

8 AdenoVerse Platform Applications A library of adenoviral vectors with diverse and unique biological properties Distinct Vector Subsets Vectors for eliciting long-lasting adaptive immune responses Vectors for immunologically stealth gene delivery Each Suited for a Broad Range of Applications Immunotherapies Vaccines Prophylactic & Therapeutic Oncolytics Gene Editing Cell Therapies CAR-T & Stem Cells Nucleic Acid Therapeutics Large Set of Therapeutic Areas Covered Oncology Infectious diseases Rare diseases Ophthalmology Neurology Cardiology Otology Rheumatology 7

9 Non-Human GC Vectors Proprietary Vectors, Excellent Performance Discovered and developed proprietary novel adenoviral vectors with outstanding properties Productive pre-ind meetings with the FDA for two product candidates Highly Immunogenic GC vectors include gorilla vectors with distinct advantages for molecular vaccines High-level, durable antibody responses High-level T cell responses Repeat administration boosts responses Highly Productive Low Human Prevalence 8

10 PRNT titer (IC 50 ) Superior Antigen Responses High-level, Durable Antibody Response Single Administration Weeks post-immunization GC46.F pu 9

11 % CD8+ IFNg+ T-Cells Superior Antigen Responses High-Level T Cell Response Single administration AdNull Ad5 Malaria genetic vaccine GC44 GC45 GC46 10

12 % CD8+ IFNg+ T Cells Superior Antigen Responses Repeat Administration Boosts Response Prime/Boost 12 Week Interval Ad Prime GC45 1E9 GC45 1E9 - Ad Boost - GC45 1E9 GC45 1E9 11

13 AdenoVerse Platform Overcoming the Known Adenovector Limitations Known General Adenovector Limitations Pre-existing immunity Innate immunity associated toxicity Vector liver sequestration AdenoVerse Adenovector Superiority GenVec develops vectors using proprietary backbones from rare human and nonhuman primate serotypes with low to no seroprevalence in the human population GenVec s vectors are deleted for E1, E3, and E4 regions, limiting the expression of viral proteins mainly responsible for innate immune responses Some GenVec vectors appear not to be sequestered in the liver and could be suitable for systemic delivery AdenoVerse = the next generation of adenovectors with unprecedented potential 12

14 Cellular Therapy Example TBX-02 TheraBiologics Collaboration Neural stem cells (NSCs) for directed enzyme prodrug therapy NSCs transduced by a proprietary GenVec vector express and secrete carboxylesterase (CE) for a second generation, commercializable product NSCs penetrate the tumor microenvironment, and the secreted CE enzyme provides radius of action throughout the tumor CE converts irinotecan to SN-38, which is 1,000x more toxic to tumor cells than irinotecan alone Second generation TBX-02 being developed for clinical studies SN-38 NSC CE NSC Secretes CE Irinotecan Conversion to SN-38 Tumor cell killing 13

15 AdenoVerse Vectors Applications for Differentiated Cellular Immunotherapies AdenoVerse vectors developed by GenVec for efficient T and NK cell transduction Multiple applications for adoptive cellular immunotherapies Autologous cell engineering CAR Off-the-shelf cell engineering Vector carrying gene editing or sirna payload CAR CAR CAR Patient receives autologous adenovector engineered cell therapy Patient receives off-the-shelf adenovector engineered cell therapy 14

16 Custom Gene Delivery Primary Human T Cell Transduction ADENOVERSE Data from screenings to identify vectors that efficiently transduce activated human T cells Vector A Vector B GenVec s Screening Methodology Vector C Vector D Identify vectors with preferred performance for any given application and unique need GenVec unpublished data 15

17 T Cell Gene Delivery Optimization for Efficient Delivery Relative Dose of Vector B 1X 2X 4X MFI: 90,000 MFI: 115,000 MFI: 140,000 CD3/28 activated human T cells were transduced with adenovector carrying the GFP reporter gene under CMV promoter control GenVec unpublished data 16

18 Custom Gene Delivery Natural Killer Cell Transduction ADENOVERSE Data from initial screenings to identify vectors that efficiently transduce NK cells GenVec s Screening Methodology Identify vectors with preferred performance for any given application and unique need GenVec unpublished data Vector Transduction Score Uninfected - Ad5 -/+ A + B ++ C D E -/+ F - G ++ H -/+ I ++++ J ++ K - Vector Transduction Score L -/+ M + N -/+ O +++ P Q ++ R ++++ S -/+ T ++ U - V ++++ W ++ X + 17

19 Cellular Immunotherapy Requirements Cellular Immunotherapy AdenoVerse Solutions for Key Requirements AdenoVerse Platform Solutions Manufacturing High level of transduction into immune cells, including T and NK cells High level and sustainable transgene expression Well defined, scalable, and transferable unit operations with high production yield Reduction of on-target off-tumor effects Reduction of vector integration effects Episomal transgene expression Permanent and non-permanent genetic modification of immune cells possible Adenovector is non-integrating Large capacity Delivery of a large payload for multiple gene additions and inactivations 18

20 AdenoVerse Vector Tropism Broad Range of Vectors to Support Multiple Applications Tissues In vivo applications Cell types Ex vivo applications Eye Inner ear Neural stem cells Muscle Tumor cells Lung Cardiac Keratinocytes Immune system cells (T/NK cells) 19

21 Gene Editing Solutions High Level of Complementarity and Technological Fit GenVec s AdenoVerse platform provides a unique set of solutions for the key gene editing field requirements: Gene Editing Requirements Hit and run (limited off-target effects) AdenoVerse Platform Solutions Non-integrating vector: Transient nuclease expression minimizing potential offtarget cuts Reduced chromosomal positional effects (i.e., insertion of strong promoter next to proto-oncogenes) and risk of insertional mutagenesis (i.e., endogenous gene disruption) Large Capacity Delivery of large payload (up to 12Kb): All the necessary components in a single vector Multiple expression cassettes Low Immunogenicity AdenoVerse vectors can be designed to have low immunogenicity properties 20

22 Value Through Collaborations AdenoVerse platform: Offers multiple opportunities for product development and licensing Supported by GenVec s extensive translational expertise Actively exploring opportunities to: Expand application of the platform Add complementary assets or technologies to the current portfolio Open Innovation and Collaboration to Expand the Reach and Unlock the Potential of AdenoVerse Vector Technology for New Medical Treatments 21

23 Financial Summary Common Shares Outstanding 1 Exchange: Symbol Market Capitalization 2 Cash and Investments 3 Employees 22.7 million shares NASDAQ: GNVC $8.6 million $9.6 million 15 1 As of September 7, 2016; 2 Stock price as of October 19, 2016; 3 As of June 30,

24 CONTACT: Douglas J. Swirsky President & Chief Executive Officer Rena Cohen Sr. Manager, Communications and Administration